Mark N. Diker Sells 7,000 Shares of Cantel Medical Corp. (CMD) Stock
Cantel Medical Corp. (NYSE:CMD) Director Mark N. Diker sold 7,000 shares of the stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $98.90, for a total value of $692,300.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Cantel Medical Corp. (NYSE:CMD) traded down 1.37% on Thursday, hitting $97.68. The stock had a trading volume of 53,274 shares. The firm has a 50-day moving average of $83.65 and a 200 day moving average of $77.53. Cantel Medical Corp. has a 52 week low of $68.19 and a 52 week high of $99.83. The company has a market capitalization of $4.06 billion, a price-to-earnings ratio of 57.12 and a beta of 1.25.
Cantel Medical Corp. (NYSE:CMD) last released its quarterly earnings data on Thursday, September 28th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.52 by $0.02. The firm had revenue of $205.50 million during the quarter, compared to analyst estimates of $200.32 million. Cantel Medical Corp. had a return on equity of 17.60% and a net margin of 9.27%. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. On average, analysts predict that Cantel Medical Corp. will post $2.34 earnings per share for the current year.
Several research firms have recently weighed in on CMD. Needham & Company LLC reiterated a “hold” rating on shares of Cantel Medical Corp. in a research note on Friday, September 1st. Benchmark Co. downgraded Cantel Medical Corp. from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. Zacks Investment Research downgraded Cantel Medical Corp. from a “buy” rating to a “sell” rating in a research note on Wednesday, August 2nd. Finally, Sidoti upgraded Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 price target for the company in a research note on Wednesday, August 2nd. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $91.67.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Cantel Medical Corp. in the second quarter worth about $376,271,000. Vanguard Group Inc. purchased a new stake in shares of Cantel Medical Corp. in the second quarter worth about $246,860,000. Neuberger Berman Group LLC purchased a new stake in shares of Cantel Medical Corp. in the second quarter worth about $96,236,000. Dimensional Fund Advisors LP purchased a new stake in shares of Cantel Medical Corp. in the second quarter worth about $75,756,000. Finally, Wells Fargo & Company MN purchased a new stake in shares of Cantel Medical Corp. in the second quarter worth about $75,715,000. 83.79% of the stock is owned by hedge funds and other institutional investors.
Cantel Medical Corp. Company Profile
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.